## Holaluz-Clidom, S.A.

*DISCLAIMER: This is an unofficial English translation of an original document in Spanish and is provided for information purposes only. In case of any discrepancy between this translation and the original Spanish text, the Spanish version shall prevail.*

# TO BME GROWTH

**Barcelona, 23 April 2025**

In accordance with Article 17 of Regulation (EU) No 596/2014 on market abuse and Article 227 of the consolidated text of the Securities Market and Investment Services Law, approved by Royal Legislative Decree 6/2023, of 17 March, and related provisions, as well as Circular 3/2020, Holaluz-Clidom, S.A. (the "**Company**" or the "**Firm**") hereby informs you of the following:

# OTHER RELEVANT INFORMATION

### RESOLUTIONS OF THE EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING

At the Extraordinary General Shareholders' Meeting of the Company, held on 23 April 2025, at 11:00, in first call, conducted remotely, with the attendance (in person or through representatives, as applicable), including the Company's treasury shares, of 51 shareholders holding 20,403,581 shares of the Company, representing 80.05% of the share capital, the following proposed resolutions were approved by the majorities indicated below:

### FIRST ITEM ON THE AGENDA

**Appointment of members of the Company's Board of Directors.**

**1.1 Appointment of Mr Lotfi Bellahcene as proprietary director of the Company.**

This resolution was approved with 20,245,196 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 99.22% of the capital present and/or

represented. Mr Lotfi Bellahcene is appointed as proprietary director for the statutory period of six years from the date of this General Shareholders' Meeting.

**1.2 Appointment of Mr Enrique Palau Llopis as proprietary director of the Company.**

This resolution was approved with 20,245,196 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 99.22% of the capital present and/or represented. Mr Enrique Palau Llopis is appointed as proprietary director for the statutory period of six years from the date of this General Shareholders' Meeting.

**SECOND ITEM ON THE AGENDA**

**Capital increase through debt-to-equity conversion for a nominal amount of €221,714.28 and effective amount (including share premium) of €15,519,999.60, through the issuance of new ordinary shares with a nominal value of €0.03 each, with provision for incomplete subscription. Delegation to the Board of Directors, with powers of substitution, of the necessary authority to execute the resolution and to establish the conditions not specified in the resolution in accordance with Article 297.1.a) of the Companies Act, as well as to amend Article 5 of the Articles of Association.**

This resolution was approved with 20,299,634 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 99.49% of the capital present and/or represented.

**THIRD ITEM ON THE AGENDA**

**Waiver of the corporate liability action approved by the Ordinary General Shareholders' Meeting on 28 June 2024 against Axon Partners Group Investment, S.G.E.I.C, S.A.U., represented by Mr Alfonso Juan de León Castillejo, and Geroa Pentsioak E.P.S.V. de Empleo, represented by Mr Jordan Óscar Sáenz Leal.**

This resolution was approved with 20,299,634 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 99.49% of the capital present and/or represented.

## FOURTH ITEM ON THE AGENDA

**Delegation to the Board of Directors, for a period of five years, of the authority to increase the share capital under the terms and conditions of Article 297.1.b) of the Companies Act, up to half of the share capital at the date of authorisation. Delegation of the power to exclude pre-emptive subscription rights pursuant to Article 506 of the Companies Act, limited to a maximum nominal amount, in aggregate, equal to 20% of the share capital at the date of authorisation. Revocation of previous authorisations granted under the second resolution of the Extraordinary General Shareholders' Meeting of 9 November 2021, to the extent not used.**

This resolution was approved with 15,341,373 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 75.19% of the capital present and/or represented.

## FIFTH ITEM ON THE AGENDA

**Delegation to the Board of Directors, for a period of five years, of the authority to issue bonds, debentures and other fixed-income securities convertible into shares, as well as warrants and any other financial instruments giving the right to subscribe for newly issued shares of the Company, with the power to increase the share capital to accommodate their conversion or exercise up to half of the share capital at the date of authorisation. Delegation of the power to exclude pre-emptive subscription rights pursuant to Articles 506 and 511 of the Companies Act, limited to a maximum nominal amount, in aggregate, equal to 20% of the share capital at the date of authorisation.**

This resolution was approved with 15,341,373 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 75.19% of the capital present and/or represented.

## SIXTH ITEM ON THE AGENDA

**Delegation of powers to the Board of Directors, with express power of substitution, for the formalisation, interpretation, rectification, and/or execution of the resolutions adopted by the General Meeting.**

This resolution was approved with 20,299,634 votes in favour from the 20,299,634 shares present with voting rights, representing a majority of 99.49% of the capital present and/or represented.

In compliance with the provisions of BME MTF Equity Circular 3/2020, it is hereby expressly stated that the information provided has been prepared under the sole responsibility of the Company and its directors.

**Carlota Pi Amorós**
coFounder and CEO
HOLALUZ-CLIDOM, S.A